Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 5, 2008 Brian Orelli	Yasmin Raises the Revenue Barr Barr gets a patent on Bayer's Yasmin overturned.
The Motley Fool August 8, 2008 Rich Duprey	Barr Hits a Home Run Barr gets to market Bayer's authorized generic version of contraceptive Yasmin without fear of competition for at least 180 days -- giving them a huge competitive edge over rivals.
The Motley Fool June 27, 2008 Brian Orelli	Barr's Lawyers Earn Their Keep Generic-drug maker Barr Pharmaceutical gets another patent thrown out.
The Motley Fool May 12, 2008 Brian Orelli	Lowering the Barr Barr Pharmaceuticals disappoints by lowering expectations.
The Motley Fool December 17, 2007 Brian Orelli	Barr Labs' Legal Tables Turned Barr Labs announces that is suing both Watson Pharmaceuticals and Novartis' generic subsidiary Sandoz for patent infringement regarding Barr's SEASONALE extended-cycle birth control pill.
The Motley Fool February 29, 2008 Brian Orelli	Barred by Debt The picture continues to look bleak at Barr Labs, due to debt taken on to acquire Pliva in 2006.
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool July 16, 2007 Brian Orelli	Business as Usual for Barr The maker of generic drugs gets sued twice in one week. Investors appear to be getting used to Barr's method of operation; the news of the lawsuits didn't hurt the stock price.
The Motley Fool July 28, 2009 Brian Orelli	All Growth, All the Time This generic-drug maker is no value play.
The Motley Fool December 28, 2006 Brian Lawler	Pliva's Late Christmas Gift to Barr Normally generic drug competitors, Barr Pharmaceuticals and Par Pharmaceutical Companies announced the launch of a generic version of GlaxoSmithKline's drug, Zofran. Investors, take note.
The Motley Fool July 26, 2007 Brian Orelli	Barr Gets Sued, Again This is starting to be a bad habit at Barr Pharmaceutical. The drug maker has just been sued for the third time in as many weeks. The latest one is by Schering-Plough, over patent infringement of its brain cancer treatment drug.
The Motley Fool May 28, 2008 Brian Orelli	A Rough Quarter for Generic-Drug Makers Investors rocked the smaller companies the most.
The Motley Fool August 9, 2007 Brian Orelli	Acquisition Raises Barr Half a year after acquiring a giant competitor, Barr Pharmaceuticals results appear to be on track to increase year-over-year revenues.
The Motley Fool February 23, 2007 Rich Duprey	Foolish Forecast: Barr Labs Resets Bar The pharmaceutical is set to release fourth-quarter 2006 financial results. Investors, here is what you can expect to see.
The Motley Fool December 14, 2006 Brian Lawler	Celgene Faces a Generic Challenge An abbreviated application is only an opening salvo in Barr's challenge to Celgene's Thalomid patents. Investors, take note.
Chemistry World August 24, 2009 Sarah Houlton	Indian court dismisses Bayer's patent law case Bayer has failed in its attempt to stop Indian regulators giving marketing authorization to a generic version of its kidney cancer drug Nexavar (sorafenib), despite its 20 year patent having only been granted last year.
The Motley Fool March 13, 2008 Stephen Albainy-Jenei	Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex.
The Motley Fool February 7, 2006 Stephen D. Simpson	Barr None Bargain hunters are probably going to come up short when it comes to assessing Barr Pharmaceuticals' stock, but a fairly rich package of opportunities should keep growth strong for the immediate future.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool September 19, 2006 Brian Lawler	Barr's Winning Bid The pharmaceutical wins its tug-of-war for generic drug firm Pliva. Investors would be smart to watch for any potential teething problems from the much larger and busier Barr.
The Motley Fool November 26, 2008 Brian Orelli	Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better."
The Motley Fool June 27, 2006 Stephen D. Simpson	Barr Bulks Up For Barr Labs, buying Pliva adds manufacturing capabilities, market opportunities, and pipeline candidates. Investors, take note.
The Motley Fool February 28, 2007 Brian Lawler	Barr's Becoming Big Generic drug producer Barr Pharmaceuticals announces its first quarterly earnings numbers after acquiring Pliva. Investors, take note.
The Motley Fool November 20, 2008 Brian Orelli	Sanofi Breathing Easier Drugmaker Sanofi-Aventis settles a few patent disputes with generic-drugmaker nemeses.
The Motley Fool July 30, 2007 Brian Orelli	Is Par Pharmaceutical Settling for Less? The generic drugmaker avoids going to court in some recent cases. Patent lawyers are the lifeblood of a generic drugmaker, and investors should want them to act as aggressively as possible so that Par can expand its product line.
The Motley Fool November 8, 2006 Brian Lawler	Barr's Wounded Quarter If your revenues live by the generic sword, they can die by it, too. That seems to be the case today for Barr Pharmaceuticals. Investors, take note.
The Motley Fool August 15, 2006 Stephen D. Simpson	Twirling the Barr Look closely and you'll see that Barr posted a solid quarter. Investors, if you haven't checked this one out yet, now may be the time for a little due diligence.
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
The Motley Fool November 1, 2005 Stephen D. Simpson	Belly Up to Barr Though not cheap, this is a high-quality generic drug company. However, investors must do their own due diligence and decide for themselves whether today's price offers enough margin of safety for a sound investment.
The Motley Fool July 18, 2008 Rich Duprey	More Group Therapy From Generics The Teva deal for Barr shows consolidation is still underway in the industry.
The Motley Fool September 18, 2008 Brian Orelli	Ranbaxy's Troubles Won't Help Competitors The FDA will block the importing of more than 30 drugs and ingredients until Ranbaxy's problems at two Indian manufacturing plants are resolved.
The Motley Fool June 25, 2009 Brian Orelli	Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well.
The Motley Fool August 28, 2007 Brian Orelli	Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note.
The Motley Fool September 8, 2005 Stephen D. Simpson	Raising the Barr This large generics company sees better margins and an optimistic outlook. The company has a top-notch return on assets and a valuation that, while not cheap, isn't ridiculous either.
The Motley Fool June 27, 2007 Billy Fisher	Improving Morale at Barr Preliminary OK of Barr Pharmaceutical's generic antidepressant perks up the stock's potential.
The Motley Fool July 1, 2008 Brian Orelli	As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
The Motley Fool September 11, 2006 Brian Lawler	Barr's Bidding War Barr Pharmaceuticals takes a big bite of the booming generics market. Investors, take note.
The Motley Fool April 10, 2007 Brian Lawler	Barr Issues a Challenge Barr challenges the patents on one of Sanofi's top drugs.
Managed Care September 2007 Martin Sipkoff	Patent Law Rulings Work in Favor of Generics Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
Chemistry World July 10, 2009 Sarah Houlton	Branded drugs' competition-free days numbered Authorities in the US and Europe are to look carefully at the tactics pharmaceutical firms use to delay competition from generic versions of their branded drugs.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
Pharmaceutical Executive October 1, 2005 Glass & Worrell	Whose Afraid of Authorized Generics Losing a patent challenge lets a generic competitor grab market share and slash branded profits. Sound scary? Ignoring authorized generics is worse.
The Motley Fool November 30, 2006 Brian Lawler	Not Bad, Bayer The company's buyout of fellow German firm Schering AG looks like a boon to its bottom line. Investors, take note.
BusinessWeek April 15, 2010 Naomi Kresge	As the Pill Turns 50, a Rivalry Heats Up With underserved markets in Asia beckoning, Teva is taking on Bayer, the leader in oral contraceptives
BusinessWeek January 10, 2005 Mara Der Hovanesian	Barr: A No-Name Star More than $30 billion in patents will elapse by the end of 2007, which spells new potential for generics such as Barr Pharmaceuticals. With Barr's solid pipeline, the stock, at $46, is a bargain.
Chemistry World September 2011	Column: In the pipeline Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal
The Motley Fool November 12, 2007 Brian Orelli	Raising the Barr Barr Pharmaceuticals' acquisition of Pliva increases sales, but it doesn't help raise the bottom line. Investors, take note.
The Motley Fool May 14, 2007 Brian Lawler	Mylan Goes on a Drug Binge The generic drugmaker makes a hefty acquisition, but it's hard to say at this point how good of a deal this is for shareholders.